Explore the vast range of titles available.

The impact of bacterial vaginosis on women's health is an increasing concern; however, the effect of the obesity index on bacterial vaginosis is controversial. We investigated the association between body mass index and bacterial vaginosis in women in the United States. This was a cross-sectional study which obtained the data from the National Health and Nutrition Examination Survey from 2001 to 2004, in which weighted multivariate regression and logistic regression analyses were performed to explore the independent relationship between body mass index and bacterial vaginosis. Subgroup analyses and smoothed curve fitting were also performed. A total of 5,428 participants were enrolled, and the findings show that the participants with higher body mass index tended to have a higher incidence of bacterial vaginosis. In the fully adjusted model, a positive association between bacterial vaginosis and body mass index was observed (Odd's ratio = 1.03, 95% Confidence interval, 1.01-1.04). The subgroup analysis showed that this positive association was significant in non-Hispanic White individuals (Odd's ratio = 1.0327, 95% Confidence interval, 1.0163, 1.0493). Increased bacterial vaginosis positivity may be associated with an increased body mass index.

Background Premature ovarian failure (POF) is a condition where ovarian function ceases before age 40, leading to infertility and other health issues. As public health awareness increases, platforms like TikTok and Bilibili have become key sources for health-related content. However, the absence of peer review and regulatory oversight on short-video platforms may result in the spread of inaccurate or incomplete health information. This study evaluates the quality of videos related to POF on these platforms. Methods A cross-sectional study was conducted, analyzing 187 POF-related videos from TikTok and Bilibili. The modified DISCERN and Global Quality Score (GQS) assessment tools were used to evaluate video reliability and quality. Data on video characteristics, including engagement metrics and content, were also collected. Statistical analyses were performed to assess differences between platforms, video sources, and video quality. Result TikTok is more popular than Bilibili. Videos on both platforms related to POF had suboptimal quality, with TikTok's GQS median at 3 (2–3) and Bilibili's at 2 (1–3), showing a significant difference (p < 0.05). However, both had median modified DISCERN scores of 2 (1–3), with no significant difference (p > 0.05). On Bilibili, video duration was positively correlated with quality scores (p < 0.001), but no such correlation was found on TikTok. Symptoms of POF were the most common topic, with 29% of videos providing detailed explanations. Diagnosis and treatment were discussed in 16% and 7.4% of videos, respectively. Expert-uploaded videos demonstrated significantly higher quality than those from non-experts and personal users, with GQS and modified DISCERN scores of 3 (2–4) and 2 (1–3), respectively. Conclusions TikTok had higher engagement and better quality than Bilibili, but both platforms had inadequate video quality and reliability on POF. Expert videos were more reliable. These findings highlight the need for better regulation and monitoring of health content on short-video platforms.

Objective To investigate the relationship between smoking exposure and cervical cancer risk by integrating observational and genetic evidence. Methods We analyzed data from the National Health and Nutrition Examination Survey (1999–2018) and performed a genetic instrumental variable analysis using genome-wide association studies data. Smoking exposure was assessed using self-reported status and serum cotinine concentrations. Logistic regression models were used to evaluate observational associations, while inverse variance weighting was used for genetic analysis. Results Observational analysis showed that current smokers had a significantly higher cervical cancer risk than nonsmokers and former smokers (adjusted odds ratio = 3.05, 95% confidence interval: 1.61–5.78, p < 0.001). Higher serum cotinine concentrations were also positively associated with cervical cancer risk. Genetic analysis further supported a causal link between smoking exposure and cervical cancer. Conclusions Smoking exposure significantly increases cervical cancer risk, emphasizing the importance of smoking cessation for prevention of cervical cancer. Incorporating tobacco control into cervical cancer prevention strategies could reduce disease burden.

This study aims to explore the impact of NFIC and its regulated signaling factors on epithelial ovarian cancer, providing new insights for the treatment of ovarian epithelial cancer. Bioinformatics methods were applied to predict and analyze NFIC and its downstream signaling factors. In vivo experiments involved dividing 27 purchased female nude mice into three groups: NC group, NFIC-OE group, and NFIC-OE + TBX2-OE group, to observe tumor growth in each group. In vitro experiments involved dividing the human epithelial ovarian cancer cell line SKOV3, OVCAR-3 and A2780 into five groups with different stimuli, using Western blot to observe protein expression, CCK-8 assay to observe cell proliferation, scratch assay to observe cell migration, transwell assay to observe cell invasion, Annexin V/PI assay to study apoptosis and Co-Immunoprecipitation experiment were used to study NFIC action. Bioinformatics revealed that NFIC promotes PTEN and TGFβ1, with TGFβ1 promoting the expression of TBX3 and EGR1, which in turn inhibit TBX2. Additionally, TBX2 inhibits PTEN and promotes MMPs. BRD4 promotes H3K27AC, which leads to TGFβ1 expression, while H3K27me3 inhibits TGFβ1 expression. EZH2 promotes H3K27me3, thereby inhibiting TGFβ1 and TBX3, and SP1 promotes the action of EZH2. In vivo, NFIC alleviated ovarian epithelial cancer, while TBX2 inhibited the effect of NFIC. In vitro, NFIC inhibited the expression of TBX2, nucleus SP1, EZH2, and MMPs, and promoted the expression of PTEN, nucleus BRD4, TGFβ1, and TBX3; TBX2 promoted MMPs expression. NFIC inhibited the migration and proliferation of SKOV3 cells, while TBX2 promoted it; NFIC functioned through TGFβ1 and PTEN, and their inhibition promoted the migration and proliferation of SKOV3 cells. NFIC inhibits the progression of epithelial ovarian cancer by regulating the balance of PTEN/TGFβ1/EGR1/BRD4 and SP1/EZH2 to suppress the TBX2/MMPs signaling pathway.

Background The noticeable increase in the prevalence of elevated blood pressure (BP) among children and adolescents has been a public health concern. Although physical activity (PA) intervention has been widely applied in children BP controlling programs, the effectiveness of PA intervention in adolescents over 12, the dose-response relationship between PA intervention and BP and the optimal dose of exercise required for BP lowering are all remained unclear. Current systemic review and meta-analysis aimed to offer a comprehensive evaluation of the evidence linking PA intervention to BP reduction in children and adolescents. Methods According to PRISMA and MOOSE guidelines, we searched PubMed, Embase, MEDLINE Complete, Web of Science, and the Cochrane Library up to Jul 22, 2025, for randomized controlled trails examining the association between physical activity intervention and blood pressure in children and adolescents aged 6–24 years old. Pooled weighted mean differences (WMD) were calculated using a random-effects model. Restricted cubic splines method was used to assess the dose-response association between PA intervention dose and blood pressure change. Results A total of 22 RCT studies involving 3456 subjects were included in this meta-analysis. Pooled results revealed that PA intervention was significantly associated with mean reduction in systolic blood pressure (SBP) (MD=-4.05, 95% Confidence Interval (95%CI), -6.05 to -2.06) and diastolic blood pressure (DBP) (MD=-1.95, 95% CI, -3.12 to -0.78). Both SBP and DBP showed a non-linear relationship with PA intervention dose with a max decrease at 700 MET-min/week. While the exercise intervention dose is within 0-700 MET-min/week, both DBP (β=-0.0054, p  = 0.015) and SBP (β=-0.0111, p  = 0.003) decrease as the exercise dose increases. However, when the exercise dose exceeds 700 MET-min/week, diastolic (β = 0.0059, p  = 0.049) and systolic blood pressure (β = 0.0113, p  = 0.029) rebound upward with further increases in exercise volume. Conclusion Physical activity intervention could reduce blood pressure in children and adolescents. There is a V-shape dose-response relationship between physical activity intervention dose and changes in blood pressure among adolescents, with an optimized dose of 700 MET-minutes per week.

Chimera artifacts in nanopore direct RNA sequencing (dRNA-seq) introduce substantial inaccuracies, complicating downstream applications such as transcript annotation and gene fusion detection. Current basecalling models are unable to detect or mitigate these artifacts, limiting the reliability and utility of dRNA-seq for transcriptomics research. To address this challenge, we present DeepChopper, a genomic language model specifically designed to identify and remove adapter sequences from base-called dRNA-seq long reads with single-base precision. Operating independently of raw signal or alignment information, DeepChopper effectively eliminates adapter-bridged artifacts. Here, we show that DeepChopper enhances the accuracy of downstream analyses and unlocks the full potential of nanopore dRNA-seq, establishing it as a more robust tool for diverse transcriptomics applications. Direct RNA sequencing suffers from chimera artifact contamination. Here, the authors develop DeepChopper, a genomic language model that detects artifacts with high accuracy, enabling more reliable transcriptome analysis.

Background The C-reactive protein–triglyceride glucose index (CTI) is a promising new marker for evaluating the severity of inflammation. Endometriosis (EM) is a prevalent chronic inflammatory condition influenced by estrogen, primarily affecting women of reproductive age. However, no study has demonstrated an association between the CTI and EM. Methods This cross-sectional study sourced data from females 20–50 years of age from the National Health and Nutrition Examination Survey (NHANES) 1996–2006, and included those with self-reported diagnoses of EM and sufficient information to calculate the CTI, computed as 0.412 × ln (C-reactive protein [CRP]) + ln (triglycerides [mg/dL] × fasting plasma glucose [mg/dL]/2). Multivariate logistic regression, restricted cubic splines, and subgroup analyses were performed to examine the association between the CTI and EM. Results Data from 2235 women (175 [7.82%] with EM, 2060 [92.18%] without EM [controls]), were included: those with EM exhibited a tendency toward higher CTI ( p  = 0.005), and CTI was positively associated with the prevalence of EM ( p  = 0.011). In Model 1, a 1 mg/dL increment in CTI was associated with a 56% higher prevalence of EM (odds ratio [OR] 1.563 [95% confidence interval (CI) 1.295–1.885]; P  < 0.001). This association in Model 2 (OR 1.609 [95% CI 1.334–1.941]; p  < 0.001) and Model 3 (OR 1.565 [95% CI 1.246–1.966]; p  < 0.001) remained significant. Notably, individuals in the uppermost remnant cholesterol tertile exhibited a notably higher prevalence of EM than those in the lowest tertile (OR 3.029, p  = 0.051). Restricted cubic splines revealed a nonlinear positive association between CTI and the prevalence of EM. In addition, greater EM prevalence was observed with CTI in those > 40 years of age (OR 1.57 [95% CI 1.16–2.13]), body mass index ≥ 25 kg/m 2 (OR 1.38 [95% CI 1.06–1.80]), smoking ≥ 100 cigarettes (OR 1.43 [95% CI 1.06–1.96]), married or living with partner (OR 1.41 [95% CI 1.09–1.85]), and oral contraceptive use (OR 1.35 [95% CI 1.07–1.69]). Conclusions CTI was positively associated with EM in women in the United States. Use of the CTI as an indicator of inflammation may provide new insights for the prevention and management of EM.

Objective This study aimed to evaluate the safety profile of progesterone by analyzing adverse event data from the Food and Drug Administration Adverse Event Reporting System (FAERS) between 2004 and 2024. Materials and methods This retrospective, observational pharmacovigilance study was based on data from the FAERS database. A total of 1827 adverse event reports associated with progesterone were retrieved. Disproportionality analysis methods, including the reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker, were used to evaluate the frequency, signal strength, and time-to-onset of adverse events. Results Among 24,589,239 adverse event reports in the reporting system, 1827 were associated with progesterone, covering 22 system organ classes and 152 preferred terms. The most frequently reported preferred terms were maternal exposure during pregnancy (151 cases), spontaneous abortion (144 cases), and abnormal product odor (114 cases). The top three preferred terms showing the strongest signals were decidual cast (reporting odds ratio: 2825.23), chondrodermatitis nodularis chronica helicis (reporting odds ratio: 3897.61), and autoimmune dermatitis (reporting odds ratio: 1519.29). Most adverse events occurred within 30 to 180 days after exposure. Newly identified preferred terms associated with progesterone included acute eosinophilic pneumonia, meningioma, and autoimmune dermatitis. Conclusions This study identified notable safety concerns associated with progesterone use and detected several rare adverse events. These findings underscore the need for continued monitoring, updated prescribing guidelines, and further investigation into progesterone formulations and adverse event mechanisms.

Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA is associated with adverse drug reactions. This study aimed to evaluate the adverse events (AEs) associated with MPA in by analyzing real-world data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS). By providing a comprehensive assessment of the safety profile of MPA, this study seeks to support informed clinical decision-making. Data covering the period from the first quarter of 2004 to the first quarter of 2024 were collected from the FAERS database. Disproportionality analyses were conducted using several statistical methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayesian geometric mean (EBGM). Additionally, time-to-onset (TTO) analysis was employed to quantify the signals of the MPA-associated AEs. A comprehensive dataset comprising 21,035,995 AE reports was compiled. Among these, 3,939 women reported using MPA as a contraceptive method. The reports covered 27 system organ classes (SOCs) and 25 high-frequency AE signals. Notably, significant AEs were identified, some of which were not previously detailed in the medication's prescribing information. Unforeseen significant AEs such as unintended pregnancy (n = 623; ROR, 6.65; ROR025, 6.1; χ , 2,482.38; PRR, 6.41; EBGM, 5.69; EBGM05, 5.29), bone pain (n = 35; ROR, 13.78; ROR025, 9.4; χ , 311.2; PRR, 13.75; EBGM, 10.59; EBGM05, 7.69), gait disturbance (n = 34; ROR, 2.82; ROR025, 1.99; χ , 37.31; PRR, 2.88; EBGM, 2.7; EBGM05, 2.02), dental caries (n = 15; ROR, 23.16; ROR025, 12.32; χ , 204.26; PRR, 23.14; EBGM, 15.23; EBGM05, 8.98), decrease in blood pressure (n = 15; ROR, 3.88; ROR025, 2.29; χ , 29.35; PRR, 3.88; EBGM, 3.63; EBGM05, 2.33), and osteonecrosis (n = 9; ROR, 23.44; ROR025, 10.36; χ , 123.67; PRR, 23.43; EBGM, 15.35; EBGM05, 7.75) were identified as AEs that were not previously outlined in the prescribing information of the medication. Our findings align with clinical observations, highlighting the emergence of previously unreported AE signals associated with MPA and their demographic and TTO characteristics. Further pharmaco-epidemiological studies are required to substantiate these observations.

BACKGROUNDB7H3, also known as CD276, is notably overexpressed in various malignant tumor cells in humans, with extremely high expression rates. The development of a radiotracer that targets B7H3 may provide a universal tumor-specific imaging agent and allow the noninvasive assessment of the whole-body distribution of B7H3-expressing lesions.METHODSWe enhanced and optimized the structure of an affibody (ABY) that targets B7H3 to create the radiolabeled radiotracer [68Ga]Ga-B7H3-BCH, and then, we conducted both foundational experiments and clinical translational studies.RESULTS[68Ga]Ga-B7H3-BCH exhibited high affinity (equilibrium dissociation constant [KD] = 4.5 nM), and it was taken up in large amounts by B7H3-transfected cells (A549CD276 and H1975CD276 cells); these phenomena were inhibited by unlabeled precursors. Moreover, PET imaging of multiple xenograft models revealed extensive [68Ga]Ga-B7H3-BCH uptake by tumors. In a clinical study including 20 patients with malignant tumors, the [68Ga]Ga-B7H3-BCH signal aggregated in both primary and metastatic lesions, surpassing fluorine-18 fluorodeoxyglucose (18F-FDG) in overall diagnostic efficacy for tumors (85.0% vs. 81.7%), including differentiated hepatocellular and metastatic gastric cancers. A strong correlation between B7H3 expression and [68Ga]Ga-B7H3-BCH uptake in tumors was observed, and B7H3 expression was detected with 84.38% sensitivity and 100% specificity when a maximum standardized uptake value (SUVmax) of 3.85 was set as the cutoff value. Additionally, B7H3-specific PET imaging is expected to predict B7H3 expression levels in tumor cells, intratumoral stroma, and peritumoral tissues.CONCLUSIONIn summary, [68Ga]Ga-B7H3-BCH has potential for the noninvasive identification of B7H3 expression in systemic lesions in patients with malignant tumors. This agent has prospects for improving pretreatment evaluation, predicting therapeutic responses, and monitoring resistance to therapy in patients with malignancies.TRIAL REGISTRATIONClinicalTrials.gov NCT06454955.FUNDINGThis research was financially supported by the Natural Science Foundation of Beijing Municipality (no. 7242266), the National Natural Science Foundation of China (no. 82202201), and the Young Elite Scientists Sponsorship Program by China Association for Science and Technology (CAST) (no. YESS20220230).